Aytu BioPharma (AYTU) Set to Announce Quarterly Earnings on Wednesday

Aytu BioPharma (NASDAQ:AYTU) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 13th.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.37). The firm had revenue of $17.98 million for the quarter. Aytu BioPharma had a negative net margin of 19.56% and a negative return on equity of 51.31%.

Aytu BioPharma Stock Down 0.5 %

Shares of NASDAQ AYTU opened at $1.84 on Thursday. Aytu BioPharma has a 12-month low of $1.81 and a 12-month high of $3.45. The stock has a market capitalization of $11.31 million, a PE ratio of -0.64 and a beta of -1.40. The company has a current ratio of 0.99, a quick ratio of 0.79 and a debt-to-equity ratio of 0.39. The stock’s fifty day simple moving average is $2.31 and its two-hundred day simple moving average is $2.66.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.